{"version":"1.0","provider_name":"Volity","provider_url":"https:\/\/volity.io\/fr\/","author_name":"Alexander Bennett","author_url":"https:\/\/volity.io\/fr\/alexander-bennett\/","title":"Biogen acquiert Apellis : explication des transactions de sympathie dans les fusions et acquisitions biotech","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"kDQkg2NcWE\"><a href=\"https:\/\/volity.io\/fr\/actualites\/biogen-apellis-biotech-ma-sympathy-trades\/\">Biogen acquiert Apellis : explication des transactions de sympathie dans les fusions et acquisitions biotech<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/volity.io\/fr\/actualites\/biogen-apellis-biotech-ma-sympathy-trades\/embed\/#?secret=kDQkg2NcWE\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Biogen acquiert Apellis : explication des transactions de sympathie dans les fusions et acquisitions biotech\u00a0\u00bb &#8212; Volity\" data-secret=\"kDQkg2NcWE\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/volity.io\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/biogen_apellis_trade.webp","thumbnail_width":1200,"thumbnail_height":669,"description":"Le rachat d'Apellis par Biogen pour 5,6 milliards de dollars a stimul\u00e9 les transactions de sympathie dans le secteur biotech. D\u00e9couvrez comment fonctionne la r\u00e9\u00e9valuation des fusions et acquisitions pharmaceutiques, quels titres en profitent et comment les traders se positionnent autour des transactions."}